These include VMAT2 inhibitors and antipsychotics for the treatment of chorea and movement-related symptoms, NMDA receptor antagonists for the treatment of dementia-related symptoms, antioxidants against mitochondrial metabolic dysfunction, and autophagy inducers to remove toxic mutant huntingtin protein. The gene discussed is SLC18A2; the disease is choreatic disease.